標(biāo)題: Titlebook: Drug Dosing in Obesity; Volume I: Antimicrob Syed Tabish R. Zaidi,Jason A. Roberts Book 2016 Springer International Publishing Switzerland [打印本頁] 作者: 劉興旺 時(shí)間: 2025-3-21 17:44
書目名稱Drug Dosing in Obesity影響因子(影響力)
書目名稱Drug Dosing in Obesity影響因子(影響力)學(xué)科排名
書目名稱Drug Dosing in Obesity網(wǎng)絡(luò)公開度
書目名稱Drug Dosing in Obesity網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drug Dosing in Obesity被引頻次
書目名稱Drug Dosing in Obesity被引頻次學(xué)科排名
書目名稱Drug Dosing in Obesity年度引用
書目名稱Drug Dosing in Obesity年度引用學(xué)科排名
書目名稱Drug Dosing in Obesity讀者反饋
書目名稱Drug Dosing in Obesity讀者反饋學(xué)科排名
作者: Melodrama 時(shí)間: 2025-3-21 22:33 作者: confide 時(shí)間: 2025-3-22 03:01
https://doi.org/10.1007/978-3-319-44034-7Pharmacokinetics; Infectious diseases; Physiological changes in obesity; Antibiotics; Antifungals; pharma作者: BORE 時(shí)間: 2025-3-22 07:44 作者: AGGER 時(shí)間: 2025-3-22 12:00 作者: Spinous-Process 時(shí)間: 2025-3-22 15:20 作者: Spinous-Process 時(shí)間: 2025-3-22 17:32 作者: 織物 時(shí)間: 2025-3-22 21:32 作者: sigmoid-colon 時(shí)間: 2025-3-23 05:19
H. M. Dekhuijzen,D. R. Verkerke,A. Houwersage form. The pharmacokinetics of this particular class of antibiotics varies significantly among individual agents, thus preventing a uniform approach to dose adjustment. Relatively more data is available for ciprofloxacin and levofloxacin compared to other agents in this class. This chapter outlin作者: 我吃花盤旋 時(shí)間: 2025-3-23 08:17 作者: 圣歌 時(shí)間: 2025-3-23 11:50 作者: DOLT 時(shí)間: 2025-3-23 15:43 作者: gain631 時(shí)間: 2025-3-23 21:23
D. Creel,H. Spekreijse,D. Reitsaspofungin and micafungin. They have broad spectrum activity against the majority of . and . species and consensus guidelines recommend echinocandins for the treatment of invasive candidiasis, for salvage therapy for invasive aspergillosis and for prophylaxis for invasive candidiasis in select high 作者: 無辜 時(shí)間: 2025-3-23 22:56 作者: grounded 時(shí)間: 2025-3-24 03:35
Observations of Faint Globular Clustersmation on the pharmacokinetics (PK) variability or dosing strategies for obese patients. This chapter will briefly outline the literature and dosing recommendations for other miscellaneous antimicrobials that are not presented elsewhere in this book. Dosing recommendations for these agents in obese 作者: 勉勵(lì) 時(shí)間: 2025-3-24 07:17
Book 2016written by a group of doctors and pharmacists working in infectious diseases practice and research...The introductory chapter outlines the important physiological changes in obesity including factors affecting the dosing of antimicrobials in obese patients. The introductory chapter is followed by te作者: 懸崖 時(shí)間: 2025-3-24 13:23
M. A. Beran,F. Alayne Street-Perrottstanding of the focus of infection, relative susceptibilities of the micro-organism involved, the best match of the body size descriptor for the antimicrobial in question and the renal function of the patients under treatment.作者: BLANK 時(shí)間: 2025-3-24 15:37
H. M. Dekhuijzen,D. R. Verkerke,A. Houwerse significant dose related adverse effects and therefore, the clinical need of a flouroquinolone should be carefully considered before using them in obese patients, who are likely to receive higher than the usually recommended doses.作者: peak-flow 時(shí)間: 2025-3-24 21:13 作者: 昏暗 時(shí)間: 2025-3-25 01:55
Introduction,standing of the focus of infection, relative susceptibilities of the micro-organism involved, the best match of the body size descriptor for the antimicrobial in question and the renal function of the patients under treatment.作者: Ejaculate 時(shí)間: 2025-3-25 03:36 作者: 手銬 時(shí)間: 2025-3-25 08:44 作者: 疼死我了 時(shí)間: 2025-3-25 11:57
Miscellaneous Agents,patients have been made based on the limited available information. There is an urgent need for robust PK studies of many antibiotics that are commonly used in obese patients to guide dosing recommendations.作者: maudtin 時(shí)間: 2025-3-25 18:35 作者: 恩惠 時(shí)間: 2025-3-25 23:40
N. Bhandari,V. N. Nijampukar,C. P. Vohras in obesity and dosing recommendations are scarce. The purpose of this chapter is to review and summarise the published data to assist in developing dosing recommendations for the use of cephalosporins in obesity.作者: 曲解 時(shí)間: 2025-3-26 03:59
R. B. Austin,C. L. Morgan,M. A. Fordccurate initial dosing regimens can be achieved by using a correction factor for obesity when estimating a volume of distribution (V). While for subsequent doses, therapeutic drug monitoring (TDM) remains an essential tool to guide dosing and to prevent unwanted adverse events such as nephrotoxicity.作者: Pericarditis 時(shí)間: 2025-3-26 07:20 作者: Urgency 時(shí)間: 2025-3-26 12:18 作者: 招人嫉妒 時(shí)間: 2025-3-26 12:53 作者: fabricate 時(shí)間: 2025-3-26 18:10 作者: abstemious 時(shí)間: 2025-3-26 22:45 作者: 異端邪說2 時(shí)間: 2025-3-27 04:17
Aminoglycoside Dosing in Obesity,ccurate initial dosing regimens can be achieved by using a correction factor for obesity when estimating a volume of distribution (V). While for subsequent doses, therapeutic drug monitoring (TDM) remains an essential tool to guide dosing and to prevent unwanted adverse events such as nephrotoxicity.作者: Radiation 時(shí)間: 2025-3-27 07:24 作者: 很是迷惑 時(shí)間: 2025-3-27 10:20
Azole Antifungal Agents, advancements in drug delivery, efficacy, monitoring and side effect profiling. Pharmacokinetic changes and dose guidance for these agents in the obese population will be addressed following a review of the available literature.作者: 不近人情 時(shí)間: 2025-3-27 17:17 作者: confederacy 時(shí)間: 2025-3-27 18:18 作者: 乳白光 時(shí)間: 2025-3-28 00:26
Penicillins, sepsis. Clinical efficacy and the prevention of the emergence of resistance are critically dependent upon the correct dosing strategy in order to meet the required time-dependent pharmacodynamic target. Penicillins mainly experience increases in volume of distribution and renal clearance in obese p作者: Breach 時(shí)間: 2025-3-28 02:05
Cephalosporins,nfections. Compared with other antibiotics such as vancomycin and aminoglycosides, there is a paucity of data on the pharmacokinetics of cephalosporins in obesity and dosing recommendations are scarce. The purpose of this chapter is to review and summarise the published data to assist in developing 作者: Working-Memory 時(shí)間: 2025-3-28 06:48 作者: verdict 時(shí)間: 2025-3-28 11:42
Fluoroquinolones,age form. The pharmacokinetics of this particular class of antibiotics varies significantly among individual agents, thus preventing a uniform approach to dose adjustment. Relatively more data is available for ciprofloxacin and levofloxacin compared to other agents in this class. This chapter outlin作者: Ccu106 時(shí)間: 2025-3-28 16:33 作者: propose 時(shí)間: 2025-3-28 19:02
Glycopeptides and Antibiotics for Gram-positive Bacterial Infections,ns caused by Gram-positive bacteria. Limited information is available about the dosing of these antibiotics in obese patients. This chapter aims to summarise the available evidence on the dosing of glycopeptides, lipopeptides, linezolid and quinupristin/dalfopristin in obesity. Specific dosing recom作者: STAT 時(shí)間: 2025-3-29 02:56
Azole Antifungal Agents,gement of systemic fungal infections. Their application in the prophylaxis against and treatment of systemic mycoses continues to evolve, with ongoing advancements in drug delivery, efficacy, monitoring and side effect profiling. Pharmacokinetic changes and dose guidance for these agents in the obes作者: Catheter 時(shí)間: 2025-3-29 05:10 作者: Interdict 時(shí)間: 2025-3-29 09:27 作者: 遠(yuǎn)地點(diǎn) 時(shí)間: 2025-3-29 13:30 作者: 尾巴 時(shí)間: 2025-3-29 15:35
Book 2016ng up-to-date information on antimicrobial dosing in obese patients. Doctors, pharmacists, nurses working in hospital settings, and students of health courses (medical, pharmacy and nursing students) will find this book particularly useful..作者: 蝕刻術(shù) 時(shí)間: 2025-3-29 20:09 作者: intertwine 時(shí)間: 2025-3-30 02:56
